New cancer injection enters first human tests
NCT ID NCT06990464
Summary
This is a first-in-human study to test the safety and find the right dose of a new drug called SIBP-A19 for people with advanced solid tumors. It will enroll about 156 adults whose cancer has progressed despite standard treatments. The main goal is to see how much of the drug the body can handle and to check for any serious side effects, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Union Hospital affiliated to Fujian Medical University
RECRUITINGFuzhou, Fujian, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.